BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene, will give the opening ceremony keynote, “Innovating for Impact: How ...

The Company granted stock options to purchase up to an aggregate of 69,000 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on October 15, 2024.

Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of ...

Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in patients with a form of lung cancer. The Shanghai-based biopharmaceutical company ...

Dimensional Fund Advisors LP boosted its stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) by 103.2% during the 2nd quarter, according to the company in its most recent disclosure ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at ...

MONTREAL, Oct. 15, 2024 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company, received positive top-line results from the Wave I Part 2 proof-of-concept clinical study evalua ...

Systemic JAK inhibitor therapy with tofacitinib was associated with the most favorable outcomes among patients with extensive vitiligo.

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

Title: Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2) Presenting Author: Sara Cano-Crespo, Ph.D., Gain Therapeutics Poster Session: Molecular Targeted Agents Date ...